CardioMech Appoints Ramin Mousavi as Board Chairman to Boost Mitral Valve Innovation

CardioMech Strengthens Leadership with New Chairman

In a pivotal move for its innovative medical device technology, Norway’s CardioMech AS has appointed Ramin Mousavi as Chairman of the Board. This announcement, made on June 24, 2026, marks a significant step forward for the company as it aims to further develop its catheter-based, minimally invasive mitral valve repair technology.

Ramin Mousavi brings to CardioMech an impressive background in medical technology, having previously served in senior positions at renowned companies including CathWorks, an organization acquired by Medtronic just months prior to his appointment. His expertise spans cardiovascular health, structural heart solutions, and neurovascular technologies.

Rick Nehm, President and CEO of CardioMech AS, expressed his enthusiasm about the new appointment. He stated, “With his unique experience in developing and launching groundbreaking technologies, including transcatheter heart valves, we are honored to welcome Ramin to our team.” Mousavi’s role will include collaborating closely with CardioMech’s board and leadership to accelerate advancements in treatments for degenerative mitral regurgitation (DMR), a serious condition affecting numerous patients worldwide.

Mousavi himself acknowledged the critical nature of CardioMech’s mission. He remarked, “CardioMech is addressing substantial unmet needs in structural heart treatment with potentially disruptive technologies that aim to combine the safety of minimally invasive techniques and the effectiveness of traditional surgeries.” His sentiments are echoed by medical experts emphasizing the urgency for new methods to manage mitral regurgitation, which can lead to severe health complications if untreated.

The company’s goal aligns with a growing demand for innovative solutions in cardiovascular medicine, particularly for younger patients who might benefit significantly from early intervention. As Mousavi mentioned, the company’s technology is designed not only to eliminate mitral regurgitation but also to keep future treatment options open, presenting a more holistic approach to heart health.

CardioMech AS is committed to transforming the standard of care through its specialized technology, and the appointment of Mousavi as Chairman emphasizes its dedication to ensuring that its advancements reach the patients who need them most. As the healthcare landscape evolves, CardioMech stands at the forefront, poised to lead the way in innovative cardiac solutions. For more information about CardioMech and its initiatives, visit CardioMech’s website.

This strategic appointment indicates a promising future for CardioMech as it continues to innovate and address pressing challenges within the realm of cardiovascular treatment. The company appears ready to make substantial contributions to the field, bolstered by Mousavi’s leadership and industry expertise.

As this journey unfolds, the medical community watches closely, eager to see how CardioMech’s advancements will shape the future of patient care and improve outcomes for those affected by heart valve issues.